- Vaccine Development
- CDC COVID-19 Vaccination Resources (mRNA Vaccine Mechanism Diagram)
- Nature – SARS-CoV-2 Vaccines in Development (September 2020) (Pfizer/Moderna vs AZ/Oxford Phase III Diagram)
- Vaccine Development Trackers: LSHTM, NYT, STAT News (Vaccine Types Infographic / More Types)
- A Guide to Vaccinology: From Basic Principles to New Developments
- Maintaining Safety with SARS-CoV-2 Vaccines
- ACIP Interim Recommendations for Vaccine Allocation
- NEJM: COVID-19 Vaccine Frequently Asked Questions
- Important Publications
- Spike Protein Conformational Dynamics: Lu M, et al. Real-Time Conformational Dynamics of SARS-CoV-2 Spikes on Virus Particles. Cell Host Microbe. Nov 2020.
- “Full Spike Plus 2P” Paper: Pallesen J, et al. Immunogenicity and Structures of a Rationally Designed Prefusion MERS-CoV Spike Antigen. Proc Natl Acad Sci USA. Aug 2017.
- mRNA in vivo → Protein: Wolff J, et al. Direct Gene Transfer into Mouse Muscle In Vivo. Science. Mar 1990
- Context: Pardi N, et al. mRNA Vaccines — A New Era in Vaccinology. Nat Rev Drug Discov. Jan 2018.
- Pfizer-BioNTech Vaccine (Tozinameran) [Visualization]
- FDA Fact Sheet for Healthcare Providers
- FDA Fact Sheet for Patients
- FDA EUA Letter (Justification Memo)
- CDC Clinical Info and Considerations
- Phase 3 Trial Data
- FDA Pfizer-BioNTech Vaccine Briefing Documents
- Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N Engl J Med. Dec 2020. (NEJM Summary)
- Efficacy — 94.8% ≥7 Days After Second Dose (52.4% After First Dose, 90.5% ≤ 7 Days After Second Dose: 90.5%); Thus, It Will Take 4 Weeks from the First Vaccine Dose to Develop Robust Protective Immunity (Doses Separated by 3 Weeks / See FDA Briefing Documents)
- Special Populations
- CDC Clinical Consideration
- ACOG: Vaccinating Pregnant and Lactating Patients Against COVID-19
- ACAAI Guidance on Risk of Allergic Reactions
- Moderna Vaccine (mRNA-1273) [Visualization]
- FDA Fact Sheet for Healthcare Providers
- FDA Fact Sheet for Patients
- FDA EUA Letter (Justification Memo)
- CDC Clinical Info and Considerations
- Phase 3 Trial Data
- FDA Briefing Documents
- Baden LR, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. Dec 2020. (NEJM Summary)
- Efficacy — 94.1% After Second Dose; Thus, It Will Take 6–8 Weeks from the First Vaccine Dose to Develop Robust Protective Immunity (Doses Separated by 4 Weeks / See FDA Briefing Documents)
- mRNA-1273 Appears to Reduce Asymptomatic Infections and Transmission By ~67% (See FDA Briefing Addendum)
- Impact: Swan DA, et al. Vaccines That Prevent SARS-CoV-2 Transmission May Prevent or Dampen a Spring Wave of COVID-19 Cases and Deaths in 2021. Dec 2020. (Not Peer Reviewed)
- Special Populations
- Oxford–AstraZeneca Vaccine (AZD1222/ChAdOx1 nCoV-19) [Visualization]
- Phase 3 Trial Data
- Voysey M, et al. Safety and Efficacy of the ChAdOx1 nCoV-19 Vaccine (AZD1222) against SARS-CoV-2: An Interim Analysis of Four Randomised Controlled Trials in Brazil, South Africa, and the UK. Lancet. Dec 2020. (Accompanying Commentary / Commentary by Biostatistician Natalie Dean)
- Ramasamy MN, et al. Safety and Immunogenicity of ChAdOx1 nCoV-19 Vaccine Administered in a Prime-Boost Regimen in Young and Old Adults (COV002): A Single-Blind, Randomised, Controlled, Phase 2/3 Trial. Lancet. Nov 2020.
- Allergic reactions occur in 11.1 cases per million doses; 71% of which occurred within 15 mins of vaccination (see MMWR).